Xenon Pharmaceuticals Inc’s recent filing unveils that its PRESIDENT & CEO MORTIMER IAN unloaded Company’s shares for reported $0.9 million on Jan 24 ’25. In the deal valued at $40.20 per share,22,468 shares were sold. As a result of this transaction, MORTIMER IAN now holds 31,302 shares worth roughly $1.12 million.
Then, MORTIMER IAN sold 16,315 shares, generating $660,806 in total proceeds. Upon selling the shares at $40.50, the PRESIDENT & CEO now owns 31,302 shares.
Before that, MORTIMER IAN sold 16,217 shares. Xenon Pharmaceuticals Inc shares valued at $649,977 were divested by the PRESIDENT & CEO at a price of $40.08 per share. As a result of the transaction, MORTIMER IAN now holds 31,302 shares, worth roughly $1.12 million.
Deutsche Bank initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on February 11, 2025; the price target was $67. H.C. Wainwright began covering XENE with “Buy” recommendation on October 01, 2024. Citigroup started covering the stock on January 04, 2024. It rated XENE as “a Buy”.
Price Performance Review of XENE
On Monday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock fall -3.32% to $35.79. Over the last five days, the stock has lost -6.72%. Xenon Pharmaceuticals Inc shares have fallen nearly -8.70% since the year began. Nevertheless, the stocks have fallen -25.19% over the past one year. While a 52-week high of $50.99 was reached on 01/02/25, a 52-week low of $33.27 was recorded on 02/28/25. SMA at 50 days reached $39.25, while 200 days put it at $40.12.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 34.63, which if violated will result in even more drops to 33.46. On the upside, there is a resistance level at 37.39. A further resistance level may holdings at 38.99. The Relative Strength Index (RSI) on the 14-day chart is 34.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.56%. Stochastics %K at 39.78% indicates the stock is a holding.
The most recent change occurred on December 08, 2023 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $63 price target.
